Last reviewed · How we verify

encorafenib + binimetinib — Competitive Intelligence Brief

encorafenib + binimetinib (encorafenib-binimetinib) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: This arm of the Strata PATH trial will assess the clinical benefit of Braftovi® (encorafenib) + Mekt. Area: Oncology.

discontinued This arm of the Strata PATH trial will assess the clinical benefit of Braftovi® (encorafenib) + Mekt Oncology Live · refreshed every 30 min

Target snapshot

encorafenib + binimetinib (encorafenib-binimetinib) — Pfizer Inc.. This arm of the Strata PATH trial will assess the clinical benefit of Braftovi® (encorafenib) + Mekt

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
encorafenib + binimetinib TARGET encorafenib-binimetinib Pfizer Inc. discontinued This arm of the Strata PATH trial will assess the clinical benefit of Braftovi® (encorafenib) + Mekt

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (This arm of the Strata PATH trial will assess the clinical benefit of Braftovi® (encorafenib) + Mekt class)

  1. Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). encorafenib + binimetinib — Competitive Intelligence Brief. https://druglandscape.com/ci/encorafenib-binimetinib. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: